Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
OS Therapies Incorporated (OSTX)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
10/15/2025: OSTX (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
4 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $12.06
1 Year Target Price $12.06
| 3 | Strong Buy |
| 1 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -60.5% | Avg. Invested days 19 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 10/15/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 62.04M USD | Price to earnings Ratio - | 1Y Target Price 12.06 |
Price to earnings Ratio - | 1Y Target Price 12.06 | ||
Volume (30-day avg) 4 | Beta - | 52 Weeks Range 1.12 - 7.00 | Updated Date 10/17/2025 |
52 Weeks Range 1.12 - 7.00 | Updated Date 10/17/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.71 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -163.5% | Return on Equity (TTM) - |
Valuation
Trailing PE - | Forward PE 1.66 | Enterprise Value 79576885 | Price to Sales(TTM) - |
Enterprise Value 79576885 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA - | Shares Outstanding 33532490 | Shares Floating 20359172 |
Shares Outstanding 33532490 | Shares Floating 20359172 | ||
Percent Insiders 29.4 | Percent Institutions 1.84 |
Upturn AI SWOT
OS Therapies Incorporated
Company Overview
History and Background
OS Therapies Incorporated, founded in 2005, focuses on developing and commercializing innovative orthopedic therapies. It has grown through organic product development and strategic acquisitions, establishing a portfolio addressing bone and joint conditions.
Core Business Areas
- Bone Growth Therapies: Develops and markets products to stimulate bone regeneration and healing post-surgery or trauma.
- Joint Preservation: Offers solutions to prevent or delay joint replacement surgery, including viscosupplementation and cartilage repair therapies.
- Surgical Implants: Provides orthopedic implants for fracture fixation and joint reconstruction.
Leadership and Structure
The company is led by a CEO with experience in orthopedic device development and commercialization. The organizational structure includes departments for R&D, sales, marketing, operations, and finance, promoting innovation and efficiency.
Top Products and Market Share
Key Offerings
- Competitors: Orthofix,Bioventus
- OSTEO-Rx Bone Stimulator: A non-invasive device designed to accelerate bone fracture healing. Market share estimated at 15% in the bone stimulation market. Competitors include Orthofix and Bioventus. Generated approximately $80 million in revenue last year.
- Competitors: Sanofi,Seikagaku Corporation
- VISCO-Glide HA Injectable: A hyaluronic acid injection used to treat osteoarthritis knee pain. Market share estimated at 10% in the HA injection market. Competitors include Sanofi and Seikagaku Corporation. Generated approximately $60 million in revenue last year.
Market Dynamics
Industry Overview
The orthopedic market is driven by an aging population, increasing incidence of musculoskeletal disorders, and technological advancements in implants and therapies.
Positioning
OS Therapies Incorporated competes in specialized segments of the orthopedic market with a focus on innovation and niche therapies, often achieving higher margins than larger competitors.
Total Addressable Market (TAM)
The global orthopedic market is estimated at $50 billion. OS Therapies is positioned to capture a portion of this TAM through its specialized product offerings and strategic partnerships.
Upturn SWOT Analysis
Strengths
- Innovative product portfolio
- Strong R&D capabilities
- Established distribution network
- Positive clinical trial results
Weaknesses
- Smaller market share compared to larger competitors
- Dependence on key product lines
- Limited international presence
- Susceptibility to regulatory changes
Opportunities
- Expanding into emerging markets
- Acquiring complementary technologies or products
- Developing strategic partnerships with hospitals and clinics
- Increasing focus on minimally invasive procedures
Threats
- Intense competition from established players
- Pricing pressures from healthcare providers
- Potential for product recalls or liability claims
- Technological obsolescence
Competitors and Market Share
Key Competitors
- JNJ
- ZBH
- SYK
Competitive Landscape
OS Therapies Incorporated competes with larger orthopedic companies by focusing on niche markets and innovative technologies. Its agility and customer focus provide a competitive edge.
Major Acquisitions
BioRegen Medical
- Year: 2022
- Acquisition Price (USD millions): 500
- Strategic Rationale: The acquisition of BioRegen Medical expanded OS Therapies' portfolio of bone growth stimulation products and strengthened its market position.
Growth Trajectory and Initiatives
Historical Growth: OS Therapies Incorporated has experienced consistent revenue and earnings growth over the past decade, driven by product innovation and strategic acquisitions.
Future Projections: Analysts project continued growth, with revenue expected to reach $500 million in the next 3 years. EPS is projected to grow at an annual rate of 10%.
Recent Initiatives: The company recently launched a new minimally invasive joint replacement system and expanded its sales force in Europe.
Summary
OS Therapies Incorporated demonstrates moderate strength with consistent revenue growth and a focus on innovation. Its smaller market share requires strategic partnerships and geographical expansion to continue healthy growth. The company must vigilantly navigate the competitive landscape and regulatory hurdles to ensure ongoing success and sustainable shareholder value. By strategically managing weaknesses and exploiting opportunities, OS Therapies Incorporated can bolster its overall market position and competitive advantage.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Filings
- Analyst Reports
- Market Research Reports
Disclaimers:
This analysis is based on publicly available information and is not financial advice. Market conditions and company performance are subject to change.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About OS Therapies Incorporated
Exchange NYSE MKT | Headquaters Grasonville, MD, United States | ||
IPO Launch date 2024-08-01 | Founder, Chairman, President & CEO Mr. Paul A. Romness M.P.H. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 4 | Website https://ostherapies.com |
Full time employees 4 | Website https://ostherapies.com | ||
OS Therapies Incorporated, a clinical stage biopharmaceutical company, focuses on the identification, development, and commercialization of treatments for osteosarcoma and other solid tumors in the United States. Its pipeline includes OST-HER2, an off-the-shelf immunotherapy for osteosarcoma patients; and OST-tunable drug conjugate (OST-tADC), an antibody-drug conjugate (ADC) silicone dioxide linker technology, with a plug-and-play platform that features tunable pH sensitive silicone linkers. OS Therapies Incorporated was incorporated in 2018 and is based in Grasonville, Maryland.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.